Found: 50
Select item for more details and to access through your institution.
Characteristics and outcomes of patients with relapsed Philadelphia chromosome‐positive acute lymphoblastic leukemia after failure of a frontline ponatinib‐containing therapy.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 7, p. 1423, doi. 10.1002/ajh.27329
- By:
- Publication type:
- Article
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT‐PCR for BCR::ABL1.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 8, p. 1196, doi. 10.1002/ajh.26949
- By:
- Publication type:
- Article
Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 3, p. 493, doi. 10.1002/ajh.26816
- By:
- Publication type:
- Article
Blinatumomab is associated with favorable outcomes in patients with B‐cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10<sup>−4</sup> and higher.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 9, p. 1135, doi. 10.1002/ajh.26634
- By:
- Publication type:
- Article
Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome‐negative B‐cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 6, p. E201, doi. 10.1002/ajh.26526
- By:
- Publication type:
- Article
Outcome of adults with relapsed/refractory T‐cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 9, p. E245, doi. 10.1002/ajh.25896
- By:
- Publication type:
- Article
Philadelphia chromosome‐positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 12, p. 1388, doi. 10.1002/ajh.25648
- By:
- Publication type:
- Article
Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 10, p. E595, doi. 10.1002/ajh.24833
- By:
- Publication type:
- Article
Poor outcomes associated with +der(22)t(9;22) and −9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 3, p. 238, doi. 10.1002/ajh.24625
- By:
- Publication type:
- Article
Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 3, p. 279, doi. 10.1002/ajh.24629
- By:
- Publication type:
- Article
Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 8, p. 819, doi. 10.1002/ajh.24419
- By:
- Publication type:
- Article
Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia.
- Published in:
- American Journal of Hematology, 2016, v. 91, p. 385, doi. 10.1002/ajh.24296
- By:
- Publication type:
- Article
Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 4, p. 385, doi. 10.1002/ajh.24296
- By:
- Publication type:
- Article
Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 3, p. 282, doi. 10.1002/ajh.23624
- By:
- Publication type:
- Article
Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 4, p. e168, doi. 10.1016/j.clml.2023.12.016
- By:
- Publication type:
- Article
Reduced-Intensity Chemotherapy Plus Inotuzumab Ozogamicin, With or Without Sequential Blinatumomab, is Highly Effective as First Salvage Treatment in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S186, doi. 10.1016/j.clml.2019.07.026
- By:
- Publication type:
- Article
Inotuzumab Ozogamicin Combined with Low-Intensity, with or without Blinatumomab vs. Intensive Therapy for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity Score Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S181, doi. 10.1016/j.clml.2019.07.016
- By:
- Publication type:
- Article
Duplex Sequencing Identifies Low Level ABL1 Kinase Domain Mutations in Untreated Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S186, doi. 10.1016/j.clml.2019.07.025
- By:
- Publication type:
- Article
Hyper-CVAD Plus Ofatumumab as Frontline Therapy for Adults with CD20 Positive Acute Lymphoblastic Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S185, doi. 10.1016/j.clml.2019.07.023
- By:
- Publication type:
- Article
Dynamic Prediction of Outcome with Longitudinal BCR-ABL1 Levels in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S180, doi. 10.1016/j.clml.2019.07.015
- By:
- Publication type:
- Article
The Impact of Smoking on Relapse and Survival in Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S180, doi. 10.1016/j.clml.2019.07.014
- By:
- Publication type:
- Article
Frontline Ofatumumab with Hyper-CVAD in CD20+ Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S256, doi. 10.1016/j.clml.2017.07.020
- By:
- Publication type:
- Article
Phase II study of hyper-CMAD with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S266, doi. 10.1016/j.clml.2017.07.036
- By:
- Publication type:
- Article
Frontline Inotuzumab Ozogamicin with Low-intensity Chemotherapy (mini-hyper-CVD) in Older Patients with Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase I/II Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S255, doi. 10.1016/j.clml.2017.07.019
- By:
- Publication type:
- Article
Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S257, doi. 10.1016/j.clml.2017.07.021
- By:
- Publication type:
- Article
A Phase II Trial of Inotuzumab Ozogamicin Combined with Mini-HyperCVD as Salvage Therapy for Relapsed/Refractory ALL.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S264, doi. 10.1016/j.clml.2017.07.032
- By:
- Publication type:
- Article
A Phase II Trial of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy for Patients with Relapsed/Refractory ALL.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S15, doi. 10.1016/j.clml.2016.07.024
- By:
- Publication type:
- Article
A Phase I/II Trial of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy as Frontline Therapy for Older Patients with ALL.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S15, doi. 10.1016/j.clml.2016.07.023
- By:
- Publication type:
- Article
Outcomes after Blinatumomab Failure in Patients with Relapsed/ Refractory (R/R) B-cell ALL (ALL).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S12, doi. 10.1016/j.clml.2016.07.019
- By:
- Publication type:
- Article
Frontline Therapy with Combination of Hyper-CVAD with Ponatinib in Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) ALL (ALL): A Phase II Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S10, doi. 10.1016/j.clml.2016.07.017
- By:
- Publication type:
- Article
Update Results of Frontline Therapy with Combination of Hyper-CMAD with Liposomal Vincristine (M) in Patients (Pts) with ALL (ALL).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S11, doi. 10.1016/j.clml.2016.07.018
- By:
- Publication type:
- Article
Propensity Score Analysis: Hyper-CVAD (HCVAD) + Ponatinib vs. HCVAD + Dasatinib in Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) ALL (ALL).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S9, doi. 10.1016/j.clml.2016.07.016
- By:
- Publication type:
- Article
Updated Results from the Phase II Study of Hyper-CVAD in Combination with Ofatumumab as Frontline Therapy for Adults with CD20 Positive (CD20+) ALL.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S6, doi. 10.1016/j.clml.2016.07.010
- By:
- Publication type:
- Article
Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 5, p. 1, doi. 10.1038/s41408-020-0329-y
- By:
- Publication type:
- Article
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia.
- Published in:
- Journal of Hematology & Oncology, 2023, v. 16, n. 1, p. 1, doi. 10.1186/s13045-023-01444-2
- By:
- Publication type:
- Article
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Prognostic factors for progression in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 15, p. 2648, doi. 10.1002/cncr.33529
- By:
- Publication type:
- Article
Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis
- Published in:
- Cancer (0008543X), 2019, v. 125, n. 15, p. 2579, doi. 10.1002/cncr.32139
- By:
- Publication type:
- Article
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.
- Published in:
- British Journal of Haematology, 2016, v. 172, n. 3, p. 392, doi. 10.1111/bjh.13834
- By:
- Publication type:
- Article
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).
- Published in:
- 2014
- By:
- Publication type:
- journal article
Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).
- Published in:
- Cancer (0008543X), 2014, v. 120, n. 23, p. 3660, doi. 10.1002/cncr.28930
- By:
- Publication type:
- Article
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.
- Published in:
- Cancer (0008543X), 2013, v. 119, n. 15, p. 2728, doi. 10.1002/cncr.28136
- By:
- Publication type:
- Article
Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
- Published in:
- Acta Haematologica, 2021, v. 144, n. 3, p. 285, doi. 10.1159/000510112
- By:
- Publication type:
- Article